Home>Topics>Stocks>Alexza Pharmaceuticals

Alexza Pharmaceuticals ALXA

  1. All
  2. Commentary
  3. Headlines
    1. Alexza resubmits drug application early, shares soar

      Headlines

      Fri, 22 Jun 2012

      (Reuters) - Alexza Pharmaceuticals Inc resubmitted the marketing application for its anti-agitation treatment earlier than expected, sending its shares up as much as 47 percent.

    2. Setback for Valeant's Drug Candidate Adusuve Staccato

      Commentary

      Mon, 11 Oct 2010

      Valeant Pharmaceuticals VRX announced Monday that its partner Alexza Pharmaceuticals ALXA received a complete response letter on drug candidate adusuve staccato (formerly known as staccato loxapine). We will maintain

    3. Dropping Coverage of Alexza

      Commentary

      Mon, 7 Sep 2009

      We are no longer providing equity research on Alexza Pharmaceuticals ALXA . We provide broad coverage of more than 1,800 companies across 91 industry groups and adjust our coverage as necessary based on client demand and investor interest.

    4. Alexza to Acquire Longtime Partner

      Commentary

      Tue, 16 Jun 2009

      Alexza Pharmaceuticals ALXA announced that it has exercised its option to purchase longtime partner Symphony Allegro in a deal expected to close in the third

    5. Cash Still a Concern for Alexza

      Commentary

      Fri, 8 May 2009

      Despite Alexza Pharmaceuticals ' ALXA success at narrowing its net loss for the first quarter, we are keeping our fair value estimate in place because of our continuing

    6. Alexza under Review

      Commentary

      Fri, 30 Jan 2009

      We are putting Alexza Pharmaceuticals ALXA under review after the firm announced that it will reduce its workforce by 33% and halt certain early-stage drug-development

    7. Positive Phase III Data for Alexza

      Commentary

      Wed, 10 Dec 2008

      Alexza Pharmaceuticals ALXA announced positive results from its second Phase III trial of its lead antipsychotic drug, AZ-004, for treatment of acute agitation

    8. Lowering Alexza's Uncertainty Rating

      Commentary

      Tue, 18 Nov 2008

      We're lowering Alexza Pharmaceuticals ' ALXA fair value uncertainty rating. Although we believe the company still represents a very speculative investment, we don't feel

    9. Raising Alexza's Uncertainty

      Commentary

      Thu, 9 Oct 2008

      We're raising our fair value estimate uncertainty rating for Alexza Pharmaceuticals ALXA to extreme, as it is looking more likely that the firm will need to raise more funds before the end of 2009 to continue its development

    10. Alexza Reports in-Line 2Q

      Commentary

      Thu, 7 Aug 2008

      On Wednesday, Alexza ALXA reported second-quarter results that were in line with our expectations. Therefore, we don't expect any changes to our fair

    « Prev12Next »
    Content Partners